<DOC>
	<DOCNO>NCT01832441</DOCNO>
	<brief_summary>This study Single arm , Single Centre trial check Safety Efficacy Bone Marrow Derived Autologous mono nuclear cell ( 100 Million per dose ) .trial conduct 36 month patient diabetes Mellitus India , Primary outcome measure abolition reduction insulin &gt; 50 percentage end 6 month ABMSCT-Any reduction requirement Insulin dosage Improvement HbA1C Level .</brief_summary>
	<brief_title>Study Safety Efficacy Bone Marrow Derived Autologous Cells Treatment Diabetes Mellitus .</brief_title>
	<detailed_description>study Single arm , Single Centre trial check Safety Efficacy Bone Marrow Derived Autologous mono nuclear cell ( 100 Million per dose ) .trial conduct 36 month patient diabetes Mellitus India , Primary outcome measure abolition reduction insulin &gt; 50 percentage end 6 month ABMSCT-Any reduction requirement Insulin dosage Improvement HbA1C Level .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<criteria>Patient suffer Diabetes Mellitus . Willingness undergo Bone Marrow derive Autologous cell Therapy . Ability comprehend explain protocol thereafter give informed consent well sign require Informed Consent form ( ICF ) study . Ability willingness regular visit hospital protocol procedure follow Patient History Immunodeficiency HIV+ , Hepatitis B , HBV History Life threaten allergic immune Mediated Reaction . site bone marrow aspiration potentially limiting Procedure . Alcohol drug abuse / dependence . Patients History Hypertension Hypersensitive .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Diabetes Mellitus stem cell [ MNCS ]</keyword>
</DOC>